BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
* To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT);
* To assess safety and anti-tumour efficacy and determine pharmacokinetic characteristics of afatinib and vinorelbine i.v.
Neoplasms
DRUG: afatinib 20mg|DRUG: afatinib 40mg|DRUG: vinorelbine IV 25 or 20mg/m2
Number of Patients With Dose Limiting Toxicities (DLTs) During 1st Course, DLTs and Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine iv. (MTD = not determined), during 1st course|Drug-related Adverse Events, Number of patients with drug-related adverse events, during the treatment period or up to 28 days after the completion of drug administration, up to 730 days
AUCτ,ss for Afatinib, area under the plasma concentration-time curve following dose at steady state over the dosing interval τ, pre-dose, 1, 2, 3, 4, 6, 7hours, and 23hours55minutes after 7th or 14th or 21th dose (as "with Vinorelbine") and 20th dose (as "without Vinorelbine")|Cmax,ss for Afatinib, maximum measured plasma concentration at steady state, pre-dose, 1, 2, 3, 4, 6, 7hours, and 23hours55minutes after 7th or 14th or 21th dose (as "with Vinorelbine") and 20th dose (as "without Vinorelbine")|AUC0-∞ for Vinorelbine, area under the blood concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity, predose, 10minutes, 0.5, 1, 4, 7 hours, 23hours55minutes after 2nd or 3rd or 4th dose (as "with afatinib") and 1st dose (as "without afatinib")|Cmax for Vinorelbine, maximum measured blood concentration, predose, 10minutes, 0.5, 1, 4, 7 hours, 23hours55minutes after 2nd or 3rd or 4th dose (as "with afatinib") and 1st dose (as "without afatinib")|Objective Tumour Response, According to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria and assessed by CT or MRI: Complete Response (CR), disappearance of all target and non-target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", Pre-treatment, every 8 weeks after start of study treatment, end of treatment
* To identify the Maximum Tolerated Dose (MTD) of afatinib in combination with vinorelbine i.v. by assessment of Dose Limiting Toxicities (DLT);
* To assess safety and anti-tumour efficacy and determine pharmacokinetic characteristics of afatinib and vinorelbine i.v.